29Jun/13

Armstrong: Doping key to winning the Tour – Cherry Hill Courier Post


Toronto Star

Armstrong: Doping key to winning the Tour
Cherry Hill Courier Post
Armstrong’s comments to Le Monde were surprising on many levels, not least because of his long-antagonistic relationship with the respected French daily that first reported in 1999 that corticosteroids were found in the American’s urine as he was
Tour de France impossible to win without doping: ArmstrongWaterloo Record
Armstrong uninvited, unwanted guest at 100th Tour – FOX19.com-Cincinnati FOX19

all 463 news articles »

28Jun/13

Home Sports Tour de France impossible to win without doping,… – Waterloo Record


euronews

Home Sports Tour de France impossible to win without doping,…
Waterloo Record
Armstrong’s interview with Le Monde was surprising on many levels, not least because of his long-antagonistic relationship with the respected French daily that first reported in 1999 that corticosteroids were found in the American’s urine as he was
Lance Armstrong: ‘Impossible’ to win Tour de France without dopingLos Angeles Times
Lance Armstrong Considers Himself Tour de France Record-Holder Still Huffington Post

all 466 news articles »

21Jun/13

Fusion IP's Diurnal gets European boost for infant hydrocortisone treatment – Proactive Investors USA & Canada


Proactive Investors USA & Canada

Fusion IP’s Diurnal gets European boost for infant hydrocortisone treatment
Proactive Investors USA & Canada
Diurnal, one of Fusion IP’s (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric 
Beaufort Securities Breakfast Today including Fusion IPProactive Investors UK

all 3 news articles »

21Jun/13

Fusion IP's Diurnal gets European boost for infant hydrocortisone treatment – Proactive Investors Australia

Fusion IP’s Diurnal gets European boost for infant hydrocortisone treatment
Proactive Investors Australia
Diurnal, one of Fusion IP’s (LON:FIP) portfolio of university spin-off companies, has cleared a major regulatory hurdel in Europe for Infacort, its hydrocortisone treatment for children. The European Medicines Agency (EMA) has approved a Paediatric 

and more »